Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Agios Pharmaceuticals (NQ: AGIO )

32.80 -0.42 (-1.26%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 708,140
Open 33.47
Bid (Size) 13.13 (2)
Ask (Size) 34.78 (1)
Prev. Close 33.22
Today's Range 32.52 - 33.52
52wk Range 19.80 - 35.50
Shares Outstanding 58,951,469
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
AGIO Stock Earnings: Agios Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024
AGIO stock results show that Agios Pharmaceuticals beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
The 3 Best Biotech Stocks to Buy Now: Q2 Edition
Investors can find some of the hottest, most explosive opportunities in these three top biotech stocks to buy now. 
Via InvestorPlace

Performance

YTD
+43.67%
+43.67%
1 Month
+18.41%
+18.41%
3 Month
+35.82%
+35.82%
6 Month
+41.14%
+41.14%
1 Year
+29.08%
+29.08%

More News

Read More
Agios Pharmaceuticals Stock Earns RS Rating Upgrade; Hits Key Benchmark
Via Investor's Business Daily
Earnings Scheduled For February 15, 2024
Via Benzinga
Earnings Preview: Agios Pharmaceuticals
Via Benzinga
7 Biotech Stocks Fighting America’s Deadliest Diseases
Via InvestorPlace
RBC Capital Maintains Outperform Rating for Agios Pharmaceuticals: Here's What You Need To Know
Via Benzinga
Agios Pharmaceuticals's Return On Capital Employed Overview
Via Benzinga
Agios Pharmaceuticals's Return On Capital Employed Insights
Via Benzinga
Agios Pharmaceuticals's Return On Capital Employed Overview
Via Benzinga
Why Is Blood Disorder Focused Agios Pharmaceuticals Stock Trading Higher Today?
Via Benzinga
Agios Pharma Surges, And Retakes Its 200-Day Line, On Promising Test Results For Thalassemia Drug
Via Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
Agios Touts Encouraging Action From Sickle Cell Disease Study With Mitapivat
Via Benzinga
Why Shares of Schrödinger Rose This Week
Via The Motley Fool
7 Biotech Stocks to Buy for 100% Returns
Via InvestorPlace
7 Biotech Stocks That Could Be the Next Big Thing
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2023
Via Benzinga
3 Under-the-Radar Biotech Stocks to Buy in 2022
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For November 17, 2022
Via Benzinga
Europe Approves Agios Pharma's Mitapivat For Adult Pyruvate Kinase Deficiency Patients
Via Benzinga
Agios Pharmaceuticals: Q3 Earnings Insights
Via Benzinga
Agios Pharmaceuticals Stock Clears Key Benchmark, Hitting 90-Plus RS Rating
Via Investor's Business Daily
Why Snap Shares Jumped 7%; Here Are 75 Biggest Movers From Yesterday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.